Agarwal Sheetal, Pal Dhananjay, Mitra Ashim K
Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri Kansas City, 5005 Rockhill Road, Kansas City, MO 64110-2499, USA.
Int J Pharm. 2007 Jul 18;339(1-2):139-47. doi: 10.1016/j.ijpharm.2007.02.036. Epub 2007 Mar 6.
Polarized epithelial non-human (canine) cell lines stably transfected with human or murine complementary DNA (cDNA) encoding for various efflux transporters (P-gp/MDR1, MRP1, MRP2, and Bcrp1) were used to study transepithelial transport of Lopinavir (LVR) and compare results with the MDCKII-wild type cells. These transmembrane proteins cause multidrug resistance by decreasing the total intracellular accumulation of drugs. Lopinavir efflux was directional and was completely inhibited by MK-571, a selective MRP family inhibitor in the MDCKII-MRP2 cell line. Similarly, LVR efflux was also inhibited by P-gp inhibitors P-gp-4008 and GF120918 in the MDCKII-MDR1 cell line. The efflux ratios of LVR in the absence of any efflux inhibitors in the MDCK-wild type, MDCKII-MDR1, MDCKII-MRP1 and MDCKII-MRP2 cell monolayers were 1.32, 4.91, 1.26 and 2.89 respectively. The MDCKII-MDR1 and MDCKII-MRP2 cells have significantly increased LVR efflux ratio relative to the parental cells due to the apically directed transport by MDR1 and MRP2 respectively. The efflux ratios in MRP2 and MDR1 transfected cell lines were close to unity in the presence of MK-571 and P-gp-4008, respectively, indicating that LVR efflux by MRP2 and P-gp was completely inhibited by their selective inhibitors. MDCKII-MRP1 cells did not exhibit a significant reduction in the LVR efflux relative to the parental cells, indicating that LVR is not a good substrate for MRP1. Transport studies across MDCKII-Bcrp1 cells indicated that LVR is not transported by Bcrp1 and is not a substrate for this efflux protein. In conclusion, this study presents direct evidence that LVR is effluxed by both P-gp and MRP2 which may contribute to its poor oral bioavailability and limited penetration into the CNS.
用编码各种外排转运蛋白(P-糖蛋白/MDR1、MRP1、MRP2和Bcrp1)的人或鼠互补DNA(cDNA)稳定转染的极化上皮非人类(犬)细胞系,用于研究洛匹那韦(LVR)的跨上皮转运,并将结果与MDCKII野生型细胞进行比较。这些跨膜蛋白通过减少药物在细胞内的总积累而导致多药耐药。在MDCKII-MRP2细胞系中,洛匹那韦外排具有方向性,并且被选择性MRP家族抑制剂MK-571完全抑制。同样,在MDCKII-MDR1细胞系中,LVR外排也被P-糖蛋白抑制剂P-gp-4008和GF120918抑制。在MDCK野生型、MDCKII-MDR1、MDCKII-MRP1和MDCKII-MRP2细胞单层中,在没有任何外排抑制剂的情况下,LVR的外排比率分别为1.32、4.91、1.26和2.89。由于MDR1和MRP2分别进行顶端定向转运,MDCKII-MDR1和MDCKII-MRP2细胞相对于亲代细胞的LVR外排比率显著增加。在存在MK-571和P-gp-4008的情况下,MRP2和MDR1转染细胞系中的外排比率分别接近1,表明MRP2和P-糖蛋白介导的LVR外排被其选择性抑制剂完全抑制。相对于亲代细胞,MDCKII-MRP1细胞的LVR外排没有显著降低,表明LVR不是MRP1的良好底物。跨MDCKII-Bcrp1细胞的转运研究表明,LVR不被Bcrp1转运,不是这种外排蛋白的底物。总之,本研究提供了直接证据,表明LVR可被P-糖蛋白和MRP2外排,这可能导致其口服生物利用度差和进入中枢神经系统的渗透率有限。